The research team at GOOS led by Professor Sadaf Farooqi are excited to announce that they have started treating patients with several different genetic conditions which cause obesity, with Setmelanotide, a melanocortin-4 receptor (MC4R) agonist. Following successful trials in three genetic obesity syndromes (POMC, PCSK1, LEPR), this new trial called ‘DAYBREAK’, will test whether Setmelanotide can lead to weight loss in people who carry variants in 31 genes which impact on the MC4R pathway. DAYBREAK is a two-stage, double-blind, placebo-controlled trial sponsored by Rhythm Pharmaceuticals that will be conducted across 12 countries.
Chief Investigator, Prof Sadaf Farooqi said:
This development is particularly exciting for us as we discovered many of these genetic conditions in patients recruited to the GOOS cohort. It is thanks to our colleagues in many NHS Trusts, the work of our researchers and collaborators and most importantly, the patients and their families that we have arrived at this point. We are delighted to be the first site to start the trial globally and offer involvement in the trial to UK patients with severe obesity driven by genetic causes.